The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis
Article first published online: 9 OCT 2006
Volume 99, Issue 1, pages 85–96, January 2007
How to Cite
Blake-James, B. T., Rashidian, A., Ikeda, Y. and Emberton, M. (2007), The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU International, 99: 85–96. doi: 10.1111/j.1464-410X.2006.06574.x
- Issue published online: 7 NOV 2006
- Article first published online: 9 OCT 2006
- Accepted for publication 16 August 2006
- 2Pathophysiology. In AbramsP, CardozoL, KhouryS, WeinA eds, Incontinence, 2nd International Consultation on Incontinence, 2nd edn., Chapt. 4. Plymouth: Plymbridge Distrubutors, UK, 2002: 203–41, , et al.
- 10Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2002; 3: CD003781, , , .
- 12Anonymous. British National Formulary 51. March 2006 edition. London: Pharmaceutical Press, 2006
- 14Study quality assessment. In KhanKS, Ter RietG, GlanvilleJ, SowdenAJ, KleijnenJ eds, Undertaking Systematic Reviews of Research on Effectiveness, 2nd edn, CRD Report Number 4, Chapt. 5. York: York Publishing Services Ltd., 2001., , , , .
- 19Combination treatment with propiverine hydrochloride plus doxazosin GITS in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicenter study. Proceedings of the International Continence Society 2004: 34th Annual Meeting with the International UroGynecological Association Paris, France 2004: Abstract 207, , et al.
- 20Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers (Abstract AUA Annual Meeting). J Urol 2004; 171 (Suppl.): Abstract 917, , .
- 21Identifying patients with benign prostatic hyperplasia with overactive bladder and determining the efficacy of combination therapy with alpha blocker and tolterodine. J Urol 2003; 169 (Suppl.): 477, Abstract 1788, , .
- 22Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia. Proceedings of the International Continence Society 2003: 33rd Annual Meeting, Florence, Italy. Abstract 508, , et al.
- 23Safety and tolerability of tolterodine in men with bladder outlet obstruction and symptomatic detrusor overactivity. Progrès En Urologie 2005; 15 (Suppl. 2): 29, Abstract, .
- 24Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns. J Urol 2002; 167 (Suppl.): 1048, Abstract.
- 25Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity. Eur Urol Suppl 2002; 1: 132, , .
- 26Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO). Neurourol Urodyn 2001; 20: 547–8 (Abstract), , .
- 27Combination treatment with an α-blocker plus an anticholinergic improves quality of life in patients with bladder outlet obstruction. A prospective, randomized, controlled study. Neurourol Urodyn 2002; 21: 308–9 (Abstract), , , , , .
- 29Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174: 1334–8, , et al.
- 31A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jap J Urol Surg 1999; 12: 525–36, , et al.
- 34Initial α-blocker and anticholinergic combined treatment in overactive bladder/benign prostatic obstruction (OAB/BPO) patients. Progrès En Urologie 2005; 15 (Suppl 2): 25 (Abstract, , , .
- 35Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious?. Proceedings of the International Continence Society 2005: 35th Annual Meeting, Montréal, Canada. Abstract 205, .
- 38The treatment of overactive bladder symptoms related to benign prostatic hyperplasia with an anticholinergic agent. NBS (J Jap Neurogenic Bladder Society) 2004; 15: 191–7, , , , , .
- 40Combination treatment with an alpha1-blocker plus an anticholinergic for the patients with suspected bladder outlet obstruction (BOO) concomitant with over-active bladder (OAB). (Abstract). Proceedings of the International Continence Society 2004; 34th Annual Meeting, with the International UroGynecological Association, Paris, France: Abstract 471, , et al.
- 41Bladder voiding dynamics in BPH patients treated with high dose flavoxate. Proceedings of the International Continence Society 1990; 20th Annual Meeting, Aarhus, Denmark. Abstract 119: 215–6, .
- 43A clinical study of bladderon in BPH patients. Med Consultation New Remedies 1982; 19: 1974–5.
- 44A clinical study of Bladderon tablets in patients with benign prostatic hypertrophy. Shinyaku Rinsho 1981; 30: 1478–80.
- 45A multicenter clinical trial of flavoxate hydrochloride. Nishinihon J Urol 1981; 43: 1055–63, , .
- 46Clinical effects of Bladderon tablets against nocturnal pollakiuria in BPH patients. Shinyaku Rinsho 1981; 30: 1617–9.
- 47A clinical study of combined therapy with Eviprostat and Bladderon tablets in BPH patients. Shinyaku Rinsho 1981; 30: 1481–3, , , .